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Abstract
Background: Recent studies have demonstrated a link between the inflammatory response,
increased cytokine formation, and neurodegeneration in the brain. The beneficial effects of anti-
inflammatory drugs in neurodegenerative diseases, such as Alzheimer's disease (AD), have been
documented. Increasing evidence suggests that acetaminophen has unappreciated anti-oxidant and
anti-inflammatory properties. The objectives of this study are to determine the effects of
acetaminophen on cultured brain neuronal survival and inflammatory factor expression when
exposed to oxidative stress.
Methods:  Cerebral cortical cultured neurons are pretreated with acetaminophen and then
exposed to the superoxide-generating compound menadione (5 μM). Cell survival is assessed by
MTT assay and inflammatory protein (tumor necrosis factor alpha, interleukin-1, macrophage
inflammatory protein alpha, and RANTES) release quantitated by ELISA. Expression of pro- and
anti-apoptotic proteins is assessed by western blots.
Results: Acetaminophen has pro-survival effects on neurons in culture. Menadione, a superoxide
releasing oxidant stressor, causes a significant (p < 0.001) increase in neuronal cell death as well as
in the release of tumor necrosis factor alpha, interleukin-1, macrophage inflammatory protein
alpha, and RANTES from cultured neurons. Pretreatment of neuronal cultures with acetaminophen
(50  μM) increases neuronal cell survival and inhibits the expression of these cytokines and
chemokines. In addition, we document, for the first time, that acetaminophen increases expression
of the anti-apoptotic protein Bcl2 in brain neurons and decreases the menadione-induced elevation
of the proapoptotic protein, cleaved caspase 3. We show that blocking acetaminophen-induced
expression of Bcl2 reduces the pro-survival effect of the drug.
Conclusion: These data show that acetaminophen has anti-oxidant and anti-inflammatory effects
on neurons and suggest a heretofore unappreciated therapeutic potential for this drug in
neurodegenerative diseases such as AD that are characterized by oxidant and inflammatory stress.
Background
Considerable evidence implicates neuroinflammation in
the pathophysiology of progressive neurodegenerative
disorders such as Alzheimer's disease (AD), Parkinson's
disease, amyotrophic lateral sclerosis, and multiple sclero-
sis (MS) [1-3]. A link between increased cytokine forma-
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tion and neurodegeneration has been demonstrated [4].
The role of non-neuronal cells in the brain, i.e. microglia,
astrocytes and endothelial cells, as sources of inflamma-
tory proteins in disorders of the nervous system has been
well documented. For example, in AD and Parkinson's
disease activated microglia have been identified in the
brain regions most affected in these disorders [5]. Astro-
cytes are an important source of cytokines and chemok-
ines in MS and other diseases of the CNS [6,7]. The
cerebral microcirculation of AD patients releases a host of
inflammatory proteins including thrombin, tumor necro-
sis factor-α (TNFα), transforming growth factor-β (TGFβ),
interleukin (IL) IL-1β, IL-6, IL-8, macrophage inhibitory
protein -1α (MIP-1α) and RANTES [8-11]. In contrast, the
role of neurons as a source of inflammatory proteins in
the brain has not been examined. A few studies have
recently shown that in spinal cord injury all CNS resident
cells, including neurons, synthesize and release cytokines
[12,13], suggesting that neurons can also be an important
source of inflammatory proteins in injury and diseases of
the nervous system.
Neurotoxic factors such as amyloid beta (Aβ) evoke oxida-
tive stress and directly injure neurons [14]. The interplay
between oxidative stress and inflammatory processes
likely contributes to neuronal death in brain injury and
disease [15-17]. However, a clear connection between
exposure to oxidative stress and release of inflammatory
mediators in brain neurons has not been shown. Thera-
peutic approaches for neurodegenerative disease are
focused on reducing oxidative stress and inflammation
through diet/life style changes and drug treatment [18-
21]. Acetaminophen is a widely used over the counter
antipyretic and analgesic drug with unappreciated antioxi-
dant and anti-inflammatory properties. For example,
acetaminophen protects hippocampal neurons and PC12
cultures from Aβ peptide-induced oxidative stress through
reduction of lipid peroxidation and by lowering cytoplas-
mic levels of peroxides [22]. Quinolinic acid, a neurotoxic
metabolite implicated in the pathogenesis of neurodegen-
erative disease, is inhibited by administration of acetami-
nophen [23]. Acetaminophen also protects dopamingeric
neurons in vitro from oxidative damage evoked by acute
exposure to 6-hydroxydopamine or excessive levels of
dopamine [24]. Acetaminophen has been shown to blunt
neuronal apoptosis via reduction of the inflammatory
transcription factor NF-kappaB [22]. Finally, work from
our laboratory also shows that low dose acetaminophen
reduces inflammatory protein release from cultured brain
endothelial cells exposed to oxidant stress [25].
The objectives of this study are to determine the effects of
oxidative stress on the inflammatory response of neurons
and whether acetaminophen affects survival and inflam-
matory protein expression when cultured neurons are
exposed to oxidative stress.
Methods
Primary neuronal cultures
Rat cerebral cortical cultures were prepared from cortices
of 18-day gestation fetuses, as previously described
[26,27]. The cells were seeded on 6-well poly-L-lysine
coated plates at a density of 3–5 × 105 cells per ml and
incubated in Neurobasal medium containing B-27 sup-
plement, antibiotic/antimycotic, glutamine (0.5 mM) and
5-fluoro-2'-deoxyuridine (20 μg/ml) to inhibit prolifera-
tion of glial cells. On day 5, fresh medium without 5-
fluoro-2'-deoxyuridine was added. Neuronal cultures
were used for experiments after 8–9 days in culture. The
primary cerebral cortical cultures utilized were enriched
for neurons (>95%). The neuronal identity of the cultures
was confirmed using immunofluroescent labeling for
beta-3 tubulin, a neuron-specific protein (Promega, Mad-
ison, WI) and glial fibrillary acidic protein (Promega).
Assessment of cell viability and apoptosis
Cell viability was assayed using the MTT assay (Promega)
as follows. Treatment medium was replaced with fresh
treatment medium containing 20 μl/ml of the Cell Titer
96 Aqueous One Solution and incubated for 20 min at
37°C after which optical density was measured at 490 nm
using a microplate reader. The quantity of soluble forma-
zan product, as measured by the amount of absorbance,
was directly proportional to the number of viable cells.
The optical density of untreated controls was set at 100%.
The number of viable cells after treatment was determined
by measuring optical density and expressing viability as
percent of untreated controls.
To assess the effect of acetaminophen-induced Bcl2
expression on neuronal viability, cerebral cortical cultures
were incubated with acetaminophen (100 μM) for 32 h.
Bcl2 expression was neutralized with 6 μg/ml of anti-
human Bcl2 antibody (R & D Systems, Minneapolis, MN)
or equivalent amount of mouse IgG for 2 h. The cells were
exposed to menadione (5 μM) for 4 h and the effect of the
neutralizing antibody on cell survival determined by MTT
assay, as described above.
Measurement of cell death by apoptosis was determined
using a cell death detection ELISA kit (Roche Diagnostic,
Mannheim). Cells were removed from plates, resus-
pended in lysis buffer and incubated for 30 min at 25°C.
The lysates were centrifuged at 200 × g for 10 min and
supernatants transferred to streptavidin-coated plates. A
mixture of anti-histone-biotin and anti-DNA-peroxidase
was added and incubated for 2 h at room temperature.
The plates were washed to remove unbound components,
and the amount of bound nucleosome determined by
spectrophotometer at 405 nm.Journal of Neuroinflammation 2009, 6:10 http://www.jneuroinflammation.com/content/6/1/10
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Detection of cytokines and chemokines
The cytokines and chemokines MIP-1α (ab9781),
RANTES (ab9783), Il-1α (ab1074), IL-1β (ab9787), and
TNFα (ab10863) released into the supernatant were
quantitated by indirect ELISA. Supernatants (100 μl) col-
lected from cerebral cortical cells after various treatments
were coated onto 96-well immulon 2HB (Fisher scien-
tific) flat bottom plates with sodium bicarbonate buffer
(0.1 M) and incubated overnight at 4°C. Non-specific
sites were blocked with 1% bovine serum albumin solu-
tion at 37°C for 45 min. The plates were incubated with
primary antibodies (AbCam, Cambridge, MA, dilution
1:1000) in bicarbonate buffer and incubated overnight at
4°C. Following extensive washing of the plate, 200 μl of
secondary IgG coupled with horseradish peroxidase (Bio-
Rad, Hercules, CA 1/1,000 dilution) was added and incu-
bated for 45 min at 37°C, in the dark. The reaction was
developed by adding 200 μl/well of o-phenylene diamine
H2O2 (Pierce, Chemicon, CA, USA) for 20 min. Optical
density was measured at 450 nm using a microplate ELISA
reader (Bio-Rad, Hercules, CA). Samples were assayed in
triplicate.
Western blot analysis
Total protein was extracted from neurons using lysis
buffer containing 0.1% SDS, 1% Triton X-100 and 0.5%
phenylmethyl sulfonylfluoride. Protein was determined
by the Bradford method using Bio-Rad protein reagents.
Equal amounts of protein were run on a 12% polyacryla-
mide gel, transferred on to a PVDF membrane, blocked
with 5% milk solution (non-fat dry milk in Tris-buffered
saline Tween-20) and immuno-blotted with Bcl2 (ab
7973,1:500), cleaved caspase (cell sciences -
96645,1:200), and GAPDH (MAB374, 1:1000) primary
antibodies and peroxidase-conjugated secondary antibod-
ies. After extensive washing to remove unbound antibod-
ies, membranes were developed with chemiluminescence
reagents. Band intensities were quantitified using Quan-
tity One software (Bio-Rad) and graphically expressed as
intensity units which reflects the average intensity over the
area of the band.
Bcl2 RNA silencing
Primary neuronal cultures were transfected with small
interfering RNA (siRNA) for Bcl2 (Sigma-Aldrich, St Louis,
MO) or scrambled siRNA (negative control) on day 5 in
culture. One hour before transfection, culture media were
replaced with media lacking antibiotics or glutamine.
Transfection reaction was prepared with 120 pmol/ml of
Bcl2 siRNA or scrambled siRNA in 100 μl of Opti-MEM
(Invitrogen, Carslbad, CA). Lipofectamine RNAiMAX
(Invitrogen, Carslbad, CA) transfection reagent (6 μl) was
diluted in 94 μl of OPTI-MEM. The siRNA mixture was
slowly added to the lipofectamine and incubated for 20
min at room temperature for complex formation. The
neuronal cultures were incubated with the siRNA lipo-
fectamine complex for 6 h, changed to fresh media, and
further incubated for 48 h. Bcl2 silencing was detected by
RT-PCR. Total RNA extracted from the cells treated with
siRNA was reverse transcribed with Bcl2 specific primers
and PCR products visualized on a 1.5% agarose gel using
UV trans-illumination.
Statistical analysis
Data from each experiment are expressed as mean ± stand-
ard deviation (SD). Comparisons between control and
treatment groups were conducted using the one-way
ANOVA followed by Bonferroni's multiple comparison
test for multiple samples. Statistical significance was
determined at p < 0.05.
Results
Neuronal survival increases with acetaminophen
Primary rat neuronal cultures were treated (32 h) with
increasing concentrations of acetaminophen (0 – 500
μM) and cell viability assessed by MTT assay. Acetami-
nophen increased neuronal survival in a dose-dependent
manner (Fig. 1). The increase in cell survival was demon-
strable at 25 μM (p < 0.01) acetaminophen and highly sig-
nificant at 50 to 300 μM (p < 0.001).
Acetaminophen protects against neuronal cell death 
induced by oxidative stress
Oxidative stress was induced in cerebral cortical neurons
by exposure of cells to either menadione or hydrogen per-
oxide (H2O2) and cell viability assessed by MTT assay.
Cortical neurons (day 9) were pretreated with acetami- nophen (0 – 500 μM) for 32 h Figure 1
Cortical neurons (day 9) were pretreated with aceta-
minophen (0 – 500 μM) for 32 h. Cell survival was quanti-
tated by MTT assay. The number of control cells, i.e. viable 
cells not exposed to any treatment, was defined as 100%. 
Data are mean ± SD from 3 separate experiments. **p < 
0.01 vs. control; ***p < 0.001 vs. control.
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Treatment of neuronal cultures for 4 h with 5 μM menadi-
one, an agent that releases superoxide [28], evoked
marked (63%; p < 0.001) cell death (Fig. 2a). Pretreat-
ment of neurons (32 h) with acetaminophen (50–300
μM), prior to menadione exposure, significantly (p < 0.01
– p < 0.001) increased cell survival. Similarly, treatment of
neurons for 4 h with 500 μM H2O2 decreased cell survival
by 71% (p < 0.001) and acetaminophen pretreatment was
able to significantly (p < 0.001) increase neuronal survival
at 50 μM (Fig. 2b).
We determined whether pre-incubation with acetami-
nophen for shorter time periods (8 to 24 h) affected the
apoptosis evoked by exposure of neurons to menadione.
The results showed that pre-incubation with acetami-
nophen for 8, 16, or 24 h significantly increased survival
compared to menadione alone (Fig. 3). Similarly, co-incu-
bation of acetaminophen with menadione was also capa-
ble of increasing cell survival compared to cells treated
with menadione alone (p < 0.001) (Fig. 3).
Menadione-induced increase in cytokines and chemokines 
is reduced by acetaminophen
To determine the effect of oxidative stress and acetami-
nophen on inflammatory protein release from neurons,
cerebral cortical cultures were exposed to 5 μM of mena-
dione for 4 h, the supernant collected and assayed by
ELISA for the presence of IL-1α, IL-1β, and TNFα. Expo-
sure of neurons to 5 μM menadione resulted in a signifi-
cant (p < 0.001) increase in release of IL-1α compared to
untreated control cells (Fig. 4a). Pre-incubation (32 h)
with acetaminophen (25 – 300 μM) significantly (p <
0.01 – 0.001) decreased the release of IL-1α (Fig. 4a).
Exposure of neuronal cultures to menadione caused an
almost 3 fold increase (p < 0.001) in IL-1β release that was
significantly (p < 0.001) inhibited by pretreatment (32 h)
of cells with acetaminophen (25 – 300 μM) (Fig. 4b).
Treatment of neuronal cultures with menadione also
caused a significant (p < 0.001) increase in release of
TNFα, although the increase was less than that demon-
strated for IL-1α or IL-1β (Fig. 4c). Pretreatment of neu-
rons with acetaminophen was able to significantly (p <
0.01 – 0.001) reduce TNFα (Fig. 4c).
Similar to the results obtained for the cytokines investi-
gated, we showed that menadione caused a significant
increase in release of chemokines MIP-1α (Fig. 5a) and
RANTES (Fig. 5b). Pretreatment (32 h) of neuronal cul-
tures with acetaminophen (25 – 300 μM) significantly (p
< 0.01–0.001) reduced release of both chemokines.
Cortical cell cultures were pre-incubated (32 h) with varying  doses (0 – 300 μM) of acetaminophen (APAP) for 32 h Figure 2
Cortical cell cultures were pre-incubated (32 h) with 
varying doses (0 – 300 μM) of acetaminophen (APAP) 
for 32 h. The cells were challenged with either menadione 
(5 μM) (Fig. 2a) or H2O2 (500 μM) (Fig. 2b) for 4 h and cell 
viability evaluated by MTT assay. Data are mean ± SD from 3 
separate experiments. **p < 0.01 vs. menadione alone; ***p 
< 0.001 vs. menadione or H2O2 alone; #p < 0.001 vs. control.
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Cerebral cortical cultures were either co-incubated or pre- treated (8, 16, or 24 h) with 100 μM of acetaminophen  (APAP) and exposed to 5 μM menadione for 4 h Figure 3
Cerebral cortical cultures were either co-incubated 
or pretreated (8, 16, or 24 h) with 100 μM of acetami-
nophen (APAP) and exposed to 5 μM menadione for 
4 h. Apoptosis was measured by ELISA quantitation of nucle-
osome fragmentation. The number of control cells i.e. viable 
cells not exposed to any treatment was defined as 100%. 
Data are mean ± SD from 3 separate experiments. ***p < 
0.001 vs. control. #p < 0.001 vs. menadione alone.
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Acetaminophen affects expression of pro and antiapototic 
proteins in cultured neurons
The ability of acetaminophen to affect neuronal apoptosis
was assessed by measuring the relative expression of pro-
and anti-apoptotic proteins by western blot analysis.
Untreated cells express a basal level of pro-apoptotic pro-
tein cleaved caspase 3 which increased significantly (p <
0.001) with 5 μM of menadione (Fig. 6a). Acetami-
nophen significantly (p < 0.05 – 0.001) blunts the expres-
sion of this protein at 50 – 300 μM (Fig. 6a).
Exposure of neurons to menadione (5 μM, 4 h) caused a
significant (p < 0.001) down regulation of the anti-apop-
totic protein Bcl2. Pre-treatment (32 h) of neurons with
acetaminophen (50–300 μM) significantly (p < 0.01–
0.001) increased expression of Bcl2 (Fig. 6b).
Using neutralizing antibodies to Bcl2 we determined that
inhibition of Bcl2 expression prevented the increase in
neuronal survival evoked by acetaminophen, suggesting
that part of the neuroprotective effect of acetaminophen
against menadione injury is mediated by an increase in
Bcl2 (Fig. 7).
We also examined whether silencing Bcl2 with siRNA had
any affect on cytokine and chemokine expression. Our
data showed that treatment of neuronal cultures with Bcl2
siRNA significantly (p < 0.05) increased release of TNFα
(31%) and MIP-1α (26%) compared to untreated cul-
tures. Bcl2 silencing did not affect the expression of IL-1β,
IL-1α, and RANTES (data not shown).
Discussion
In the current study we document that oxidative stress
causes release of inflammatory cytokines and chemokines
from neurons. A large body of data suggests that commu-
nication between oxidative and inflammatory processes
drive a deleterious "feed-forward" cycle that results in
neuronal cell death [15-17]. This interaction may be espe-
cially relevant for understanding the pathogenesis of neu-
rodegenerative diseases. The brain is very susceptible to
oxidative stress, in particular the hippocampus, which has
limited reactive oxygen species (ROS) scavengers and anti-
Cerebral cortical cultures were pre-incubated for 32 h with acetaminophen (0–300 μM) (APAP) and oxidatively stressed with  menadione (5 μM for 4 h) Figure 4
Cerebral cortical cultures were pre-incubated for 32 h with acetaminophen (0–300 μM) (APAP) and oxida-
tively stressed with menadione (5 μM for 4 h). Cytokines (a) IL-1α (b) IL-1β and (c) TNFα released into the supernatants 
were determined by indirect ELISA. Data are mean ± SD from 3 separate experiments. **p < 0.01 vs. menadione alone; ***p < 
0.001 vs. menadione alone; #p < 0.001 vs. control.
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oxidant capacity [29]. Recent studies demonstrate impor-
tant neuroprotective effects of acetaminophen that are, in
part, mediated by antioxidant actions. Acetaminophen
inhibits the formation of the Parkinson's disease toxin 1-
methyl-4-phenylpridinium in mitochondria [30,31].
Administration of acetaminophen to rats significantly
attenuates superoxide production by the neurotoxin qui-
nolinic acid [23]. Acetaminophen has also been shown to
be a potent scavenger of peroxynitrite [32]. In a study uti-
lizing C. elegans as a model system to study neuroprotec-
tive effects of various agents, acetaminophen is able to
significantly protect dopaminergic neurons from oxida-
tive stress [24]. Taken together, these data are consistent
with the results of the current study showing that acetami-
nophen significantly increases survival of neurons
exposed to the oxidant stressor menadione.
Acetaminophen dosage is critical to determining whether
the drug evokes toxic or beneficial effects. High doses of
acetaminophen have traditionally been associated with
necrosis [33,34]. Intake of large doses of acetaminophen
(300 mg/kg) results in severe hepatic necrosis [33]. In the
brain, overdose of acetaminophen (3 g/kg) causes a dra-
matic decrease of glutathione levels, ascorbic acid levels
and superoxide dismutase activity [35]. High dose aceta-
minophen (300 mg/kg) can evoke apoptosis via activa-
tion of the C-jun N-terminal kinase (JNK) pathway [36].
In contrast, low dose (350 μM) acetaminophen appears to
protect cardiac myocytes exposed to reperfusion injury via
inhibition of the mitochondrial permeability transition
pore and subsequent apoptotic pathway [37]. In the cur-
rent study we show that acetaminophen at a very low
dose, (50 μM or 8 μg/ml) well below toxic dose levels,
protects neurons exposed to oxidative stress. The molecu-
lar mechanisms of action of acetaminophen are contro-
versial and still poorly understood. Here we document
that pretreatment of neurons with acetaminophen
increases expression of Bcl2 and decreases cleaved caspase
3 levels. Thus, the ability of acetaminophen to affect both
pro- and anti-apoptotic proteins in neurons may represent
another mechanism for acetaminophen's beneficial
effects.
The relevance of inflammatory processes to neuron dys-
function, pathology and development of neurodegenera-
tive disease is supported by animal studies showing that
chronic infusion of the pro-inflammatory protein
lipopolysaccharide into the fourth ventricle of the rat
brain reproduces many of the pathological changes
observed in the AD brain [38]. Administration of NSAID
drugs at low concentration for extensive period of time
has been shown to reduce neuroinflammation [39,40].
Studies have shown that NSAID's may protect against
Alzheimer's by regulating the expression of inflammatory
proteins [41]. Despite studies showing that long-term use
of NSAIDs is associated with a lower incidence of AD,
clinical trials using NSAIDs have been ineffective at
improving cognitive function [42]. It is possible that drugs
such as NSAIDs that affect primarily or only inflammatory
mediators may not provide neuroprotection and that to
be neuroprotective therapeutics must target both oxidant
and inflammatory pathways.
Acetaminophen has traditionally not been classified as a
non-steroidal anti-inflammatory drug (NSAID) because
of its weak anti-inflammatory properties. The conclusion
that acetaminophen is a weak inhibitor of prostaglandin
(PG) synthesis, and thus inflammation, is based on stud-
ies in which prostaglandin synthesis is measured in
homogenized tissues. However, in cellular systems aceta-
minophen can inhibit prostaglandin endoperoxide H2
synthase (PGHS) with IC50 values in the range of 4–200
μM [32,43,44]. In addition, as we document in the current
study acetaminophen is able to reduce release of inflam-
Cerebral cortical cultures were pre-incubated (32 h) with  acetaminophen (0–300 μM) (APAP) and oxidatively stressed  with menadione (5 μM for 4 h) Figure 5
Cerebral cortical cultures were pre-incubated (32 h) 
with acetaminophen (0–300 μM) (APAP) and oxida-
tively stressed with menadione (5 μM for 4 h). Chem-
okines (a) MIP-1α and (b) RANTES released into the 
supernatant were determined by indirect ELISA. Data are 
mean ± SD from 3 separate experiments. #p < 0.001 vs. con-
trol; **p < 0.01 vs. menadione alone; ***p < 0.001 vs. mena-
dione alone.
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matory proteins from neurons. The idea that acetami-
nophen has beneficial effects in the brain is supported by
a recent study showing administration of acetaminophen
improves cognitive performance of rodents in the Morris
water maze test [45]. The combination of acetami-
nophen's anti-oxidant and anti-inflammatory properties
may render it a very efficacious drug for CNS diseases that
are characterized by both oxidant and inflammatory
stress.
Conclusion
In the present study we demonstrate that acetaminophen
has pro-survival effects on neurons in culture. Pretreat-
ment of cultured brain neurons with acetaminophen sig-
nificantly increases survival of cells exposed to the oxidant
stressor menadione. Also, treatment of cultured neurons
with menadione causes release of several inflammatory
proteins including RANTES, MIP-1α, TNFα, IL-1α and IL-
1β that is diminished by pretreatment of neurons with
acetaminophen. We document, for the first time, that
acetaminophen increases expression of the anti-apoptotic
protein Bcl2 in brain neurons and decreases the elevation
of the pro-apoptotic protein caspase 3 evoked by menadi-
one. We show that blocking acetaminophen-induced
expression of Bcl2 reduces the pro-survival effect of the
drug. These data show that acetaminophen has anti-oxi-
dant and anti-inflammatory effects on neurons and sug-
gest a heretofore unappreciated therapeutic potential for
this drug in neurodegenerative diseases such as AD that
are characterized by oxidant and inflammatory stress.
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